Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 463.58A |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Testosterone supplemented |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
7 |
| Average PDX Generation Time (days +/- SEM) | 67 ± 5 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304 |
| Markers | 463.58A |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 463.58A | AKT1 | 0.768 | 3.406 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | APC | -1.478 | 0.718 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | CDH1 | -0.826 | 1.128 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | CHD1 | -1.478 | 0.718 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | CHD7 | 1.534 | 5.792 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | FANCA | -0.820 | 1.133 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | FANCD2 | -0.742 | 1.196 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | FOXA1 | 0.521 | 2.869 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | GNAS | 0.539 | 2.906 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | IGF2R | -1.414 | 0.750 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | KDM6A | 1.040 | 2.056 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | KEAP1 | -0.850 | 1.109 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | MGA | -0.764 | 1.177 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | MSH2 | -0.760 | 1.181 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | MYC | 1.129 | 4.373 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | NCOR2 | 0.501 | 2.830 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | PIK3R1 | -1.478 | 0.718 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | RAF1 | -0.742 | 1.196 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | SMARCAD1 | -1.499 | 0.708 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | SMARCAD1 | -1.393 | 0.761 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | SPOP | 1.287 | 4.881 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | STAB2 | 0.486 | 2.801 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | STAB2 | 0.565 | 2.960 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | TP53 | -0.822 | 1.132 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 463.58A | XPO1 | -0.866 | 1.097 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 463.58A |
|---|---|
| Sample Site | Tumour adjacent to pancreas |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | None |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | Radiotherapy, zoladex, docetaxel, enzalutamide, niraparib, cabazitaxel |
Patient Information
| Patient Number | 455/463 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 7.8 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 463.58A |
| Patient Age (binned in 5 year age groups) | 55-59 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 463.58A | GPR124 | 241 | 1.0 | Missense variant | '8/19 | 2.04E-05 | 26.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 463.58A | TP53 | 174 | 1.0 | Stop gained | '7/11 | . | 37 | Pathogenic | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 463.58A | NCOR1 | 443 | 0.42 | Missense variant | '28/46 | 0.0007429 | 33 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 463.58A | ZFHX3 | 132 | 0.41 | Inframe insertion | '10/10 | . | . | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 463.58A | SPTA1 | 365 | 0.34 | Splice acceptor variant | . | . | 34 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table